Skip NavigationSkip to Content
Return Return to Search Results

A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis

  1. Author:
    Horne, Eric A
    Diaz, Philippe
    Cimino, Patrick J [ORCID]
    Jung, Erik
    Xu, Cong
    Hamel,Ernest
    Wagenbach, Michael
    Kumasaka, Debra
    Wageling, Nicholas B
    Azorín, Daniel D
    Winkler, Frank
    Wordeman, Linda G
    Holland, Eric C
    Stella, Nephi [ORCID]

  2. Author Address

    Department of Pharmacology, University of Washington, Seattle, Washington, USA., Stella Therapeutics, Inc., Pacific Northwest Research Institute, Seattle, Washington, USA., Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana, USA., DermaXon LLC, Missoula, Montana, USA., Department of Pathology, University of Washington, Seattle, Washington, USA., Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Developmental Therapeutics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Department of Physiology and Biophysics, University of Washington, Seattle, Washington, USA., Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA.,
    1. Year: 2021
    2. Date: Jan-Dec
    3. Epub Date: 2020 12 03
  2. Journal: Neuro-oncology advances
    1. 3
    2. 1
    3. Pages: vdaa165
  4. Type of Article: Article
  5. Article Number: vdaa165
  1. Abstract:

    Glioma is sensitive to microtubule-targeting agents (MTAs), but most MTAs do not cross the blood brain barrier (BBB). To address this limitation, we developed the new chemical entity, ST-401, a brain-penetrant MTA. Synthesis of ST-401. Measures of MT assembly and dynamics. Cell proliferation and viability of patient-derived (PD) glioma in culture. Measure of tumor microtube (TM) parameters using immunofluorescence analysis and machine learning-based workflow. Pharmacokinetics (PK) and experimental toxicity in mice. In vivo antitumor activity in the RCAS/tv-a PDGFB-driven glioma (PDGFB-glioma) mouse model. We discovered that ST-401 disrupts microtubule (MT) function through gentle and reverisible reduction in MT assembly that triggers mitotic delay and cell death in interphase. ST-401 inhibits the formation of TMs, MT-rich structures that connect glioma to a network that promotes resistance to DNA damage. PK analysis of ST-401 in mice shows brain penetration reaching antitumor concentrations, and in vivo testing of ST-401 in a xenograft flank tumor mouse model demonstrates significant antitumor activity and no over toxicity in mice. In the PDGFB-glioma mouse model, ST-401 enhances the therapeutic efficacies of temozolomide (TMZ) and radiation therapy (RT). Our study identifies hallmarks of glioma tumorigenesis that are sensitive to MTAs and reports ST-401 as a promising chemical scaffold to develop brain-penetrant MTAs. © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/noajnl/vdaa165
  3. PMID: 33506204
  4. PMCID: PMC7813200
  5. PII : vdaa165

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel